好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Levels of Evidence of Comorbid Epileptic Seizures in Patients with Functional Seizures.
Epilepsy/Clinical Neurophysiology (EEG)
P7 - Poster Session 7 (5:00 PM-6:00 PM)
9-012
To describe the clinical evidence of comorbid epileptic seizures in patients with known functional (nonepileptic) seizures.

Cessation of anti-seizure medications in patients with established functional seizures has been shown to confirm the diagnosis, increase patient satisfaction, and improve seizure outcomes. Published literature reports a wide variation in the rate of comorbid epilepsy, ranging from 10% to 60%. Our goal was to assess how often factors that raise the suspicion of comorbid epilepsy are observed in patients with functional seizures. We also propose diagnostic criteria for comorbid epilepsy, which may help in patient counseling and promote more judicious use of anti-seizure medications.

We conducted a retrospective chart review of adult patients with known functional seizures, classified with International League Against Epilepsy (ILAE) certainty as either "Clinically Established" or "Documented." We sought to identify factors linked to comorbid epilepsy in their clinical history, observed seizure semiology, neuroimaging, and EEG findings. The certainty of comorbid epilepsy was categorized into five levels: Unlikely, Possible, Probable, Clinically Established, and Documented, based on varying levels of evidence.

We included 100 patients with functional seizures (median age 37, interquartile range 28-48; 78% female).  The certainty of comorbid epilepsy was deemed unlikely in 64%, possible in 10%, probable in 13%, clinically established in 2%, and documented in 11%. The most common clinical factor that made comorbid epilepsy "possible" was nocturnal events. Interictal epileptiform discharges resulted in comorbid epilepsy being classified as "probable" in 11% of cases.

Although EEG-documented comorbid epilepsy was uncommon (11%) among patients with functional seizures, 36% of patients had some evidence suggesting comorbid epilepsy. Variations in the levels of evidence may explain the differing rates of comorbid epilepsy reported in the literature. Long-term follow-up is required to determine which patients may benefit from anti-seizure medications.
Authors/Disclosures
Shruti N. Iyer, MBBS
PRESENTER
Dr. Iyer has nothing to disclose.
Gabriela Figueiredo Pucci, MD Dr. Figueiredo Pucci has nothing to disclose.
Katherine McFarlane, MS (University of Pittsburgh) Ms. McFarlane has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Ms. McFarlane has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuropace.
Alex Israel, MD Dr. Israel has nothing to disclose.
DANIELLE R. CARNS, PsyD Dr. CARNS has nothing to disclose.
LIANNE G. Vighetti, DHCE, HEC-C, LCSW Dr. Vighetti has nothing to disclose.
Brittany W. Concilus, LCSW Miss Concilus has nothing to disclose.
Wesley Kerr, MD, PhD (University of Pittsburgh) Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Lifesciences. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Kerr has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for QurAlis. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. The institution of Dr. Kerr has received research support from NINDS. The institution of Dr. Kerr has received research support from American Epilepsy Society. The institution of Dr. Kerr has received research support from 好色先生. The institution of Dr. Kerr has received research support from SK Life Science. The institution of Dr. Kerr has received research support from Biohaven Pharmaceuticals. Dr. Kerr has received publishing royalties from a publication relating to health care.